{
  "abstract": "Plain Language Summary: What is this summary about?\n\nThis summary describes an article published in Cancer Medicine medical journal in April 2026. The article reports the results from a study called POLARIS that looked at treatment outcomes and quality of life for patients with advanced breast cancer (ABC) who also had other medical conditions (also known as comorbidities) in routine clinical practice.\n\nPatients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) ABC were included in the study, including those patients with or without comorbidities. The researchers wanted to know if the presence of comorbidities influenced treatment outcomes and quality of life in patients treated with the medicine, palbociclib plus endocrine therapy. Since patients with HR+/HER2- ABC often receive treatment over a long period of time, quality of life is an important outcome measure along with efficacy and safety outcomes.\n\nWhat are the key takeaways?\n\nThis study showed that, in routine clinical practice, patients with HR+/HER2- ABC who had fewer comorbidities tended to experience a longer time until (or before) their cancer got worse than people with more comorbidities; they also tended to live longer overall than people with more comorbidities.\n\nPatients with some blood and lymphatic system disorders tended to live a shorter amount of time before their cancer got worse than those with other medical conditions; they also tended to live a shorter amount of time overall than those with other medical conditions. Presence of comorbidities did not affect patient quality of life during treatment with palbociclib plus endocrine therapy.\n\nWhat were the main conclusions reported by the researchers?\n\nTogether with previous results from POLARIS, the results show that treatment with palbociclib given in routine clinical practice works well for a broad group of patients with HR+/HER2- ABC, including patients with comorbidities. Although, as expected, patients with more comorbidities had poorer survival outcomes, presence of comorbidities does not appear to affect patients’ quality of life during treatment.\n\nClinical trial number: NCT03280303",
  "abstract_shown": true,
  "affiliations": [
    "Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA",
    "Department of Oncology, Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX, USA",
    "William S. Gibbons Cancer Research Institute, Northwest Georgia Oncology Centers Wellstar, Marietta, GA, USA",
    "Hematology/Oncology, West Virginia University Cancer Institute, Morgantown, WV, USA",
    "Medical Oncology, Cancer Specialists of North Florida, Fleming Island, FL, USA",
    "Oncology & Hematology, Health Partners Institute, Saint Paul, MN, USA",
    "Health Partners Institute, Saint Paul, MN, USA",
    "Saint Luke’s Cancer Institute, Kansas City, MO, USA",
    "Mid-Illinois Hematology & Oncology Associates Ltd, Normal, IL, USA",
    "Saint Vincent’s Birmingham, Birmingham, AL, USA",
    "Novant Health, Winston-Salem, NC, USA",
    "Oncology Medical Group, Pfizer Inc, New York, NY, USA",
    "Biostatistics and Medical Writing, ICON Commercialization and Outcomes, ICON Plc., Blue Bell, PA, USA",
    "Oncology Clinical Statistics, Pfizer Inc, San Diego, CA, USA",
    "Statistical Research and Data Science Center, Pfizer Inc, Groton, CT, USA",
    "Global Medical Affairs, Pfizer Inc, San Francisco, CA, USA",
    "Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 18,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Debu Tripathy"
    },
    {
      "affs": [
        1
      ],
      "name": "Joanne L. Blum"
    },
    {
      "affs": [
        0
      ],
      "name": "Meghan S. Karuturi"
    },
    {
      "affs": [
        2
      ],
      "name": "Steven McCune"
    },
    {
      "affs": [
        3
      ],
      "name": "Sobha Kurian"
    },
    {
      "affs": [
        4
      ],
      "name": "Mehdi M. Moezi"
    },
    {
      "affs": [
        5
      ],
      "name": "Daniel M. Anderson"
    },
    {
      "affs": [
        6
      ],
      "name": "Yan Ji"
    },
    {
      "affs": [
        7
      ],
      "name": "Timothy J. Pluard"
    },
    {
      "affs": [
        8
      ],
      "name": "John Migas"
    },
    {
      "affs": [
        9
      ],
      "name": "Shailendra Lakhanpal"
    },
    {
      "affs": [
        10
      ],
      "name": "Erin Jepsen"
    },
    {
      "affs": [
        11
      ],
      "name": "Yao Wang"
    },
    {
      "affs": [
        12
      ],
      "name": "Monica Z. Montelongo"
    },
    {
      "affs": [
        13
      ],
      "name": "Zhe Zhang"
    },
    {
      "affs": [
        14
      ],
      "name": "Joseph C. Cappelleri"
    },
    {
      "affs": [
        15
      ],
      "name": "Eric Gauthier"
    },
    {
      "affs": [
        16
      ],
      "name": "Gabrielle B. Rocque"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0wfytw1c6qd3f.bib",
  "cited_by": 0,
  "doi": "10.1080/14796694.2026.2747581",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757527/",
  "id": "0wfytw1c6qd3f",
  "issns": [
    "1479-6694",
    "1744-8301"
  ],
  "landing_url": "https://doi.org/10.1080/14796694.2026.2747581",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Plain Language Summary"
    ],
    [
      "heading",
      "Plain Language Summary of Publication"
    ],
    [
      "openalex",
      "2730|Advanced Breast Cancer Therapies"
    ]
  ],
  "openalex": "W7225388196",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/14796694.2026.2747581?needAccess=true",
  "pmcid": "PMC13757527",
  "pmid": "42990019",
  "published": "2026-11-06",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/0wfytw1c6qd3f.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:08Z",
      "native_id": "PMC13757527",
      "source": "pmc",
      "url": "https://doi.org/10.1080/14796694.2026.2747581"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Advanced Breast Cancer Therapies",
      "subfield": "oncology"
    }
  ],
  "title": "Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS",
  "title_text": "Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:08Z",
  "url": "https://research.draconitic.com/paper/0wfytw1c6qd3f",
  "venue": "Future Oncology",
  "versions": []
}